Cowling T, Nayakarathna R, Wills AL, Tankala D, Paul Roc N, Barakat S. Early access for innovative oncology medicines: a different story in each nation. J Med Econ. 2023 Jan-Dec;26(1):944-953.
Medlior Resources
Medlior Publications
Insights on RWE and Evidence Synthesis
Frappier J, Cowling T, Durand R. Collaborative Demonstration Project in the Province of Québec for the Operationalization of Value-Based Agreement: Moving From a Vision to Implementation. ISPOR Europe 2024, Barcelona, Spain. Value in Health. 2024; 27 (12), S2.
Loorand-Stiver L, Cowling T, Perras C. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives. Ottawa; Canadian Agency for Drugs and Technologies in Health (CADTH); 2013 Oct [updated 2016 Feb]. (Environmental scan; issue 42).
Cowling T, de Léséleuc L. Reprocessing of single-use medical devices: a 2015 update. [Environmental Scan; Issue 48]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2015.
Cowling T, de Léséleuc L. Surgical interventions performed outside the hospital operating room. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2015. (Environmental Scan; Issue 49).
Cowling T, Boucher M. (2016). Environmental Scan on Pharmaceuticals Requiring Companion Diagnostics. International Journal of Technology Assessment in Health Care. 32(5), 327-336.
Cowling T, Pant S. Single drug technology assessment processes across health technology assessment organizations. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2016 Nov. (Environmental Scan; Issue 55).
Pant S, Cowling T, Chelak K, Kaunelis D. Opioid formulations with tamper-resistance or abuse-deterrent features — products and policies. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017. (Environmental scan; no. 62).
Cowling T, Jones S. Topical antibiotics for infected wounds: A review of the clinical effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017 Mar. (CADTH rapid response report: summary with critical appraisal).
Cowling T, Dolcine B. Point-of-care testing. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2017 Oct. (Environmental scan; no. 65).
Cowling T, Jones S. Gene therapy: international regulatory and health technology assessment (HTA) activities and reimbursement status. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2018. (Environmental scan; no. 71)
Cowling T, Frey N. Macrocyclic and Linear Gadolinium Based Contrast Agents for Adults Undergoing Magnetic Resonance Imaging: A Review of Safety Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 Mar. (CADTH rapid response report: summary with critical appraisal).
Cowling T, Farrah K. Fluoroquinolones for the Treatment of Other Respiratory Tract Infections: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 May (CADTH rapid response report: summary with critical appraisal).
Cowling T, Loshak H. An Overview of Liquid Biopsy for Screening and Early Detection of Cancer. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2019 Nov. (CADTH Issues in Emerging Health Technologies; Issue).
Cowling T, Graves E, Loshak H. Canadian Agency for Drugs and Technologies in Health (CADTH) Emerging Health Technology for COVID-19: Virus-neutralizing monoclonal antibodies against SARS-CoV-2. Ottawa: CADTH; 2020 Dec. (CADTH Horizon Scan Report).
Longstaff W, Filkowski J, Severn M. CADTH Health Technology Review: The Small House Model to Support Older Adults in Long-Term Care. Canadian Journal of Health Technologies, 2022.
Cowling T, Neilson H, Nayakarathna R, Mahood Q. Low-dose ipilimumab in combination with nivolumab or pembrolizumab for the treatment of advanced melanoma. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2022 July (CADTH Health Technology Review).
Nayakarathna R, Neilson H, MacDougall D, Cowling T. Virtual care use in primary care or specialty care settings. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2022 August (CADTH Health Technology Review).
Lachance CC, Darvesh N, McGill SC, Butcher R, Gates M, Kim J, Nayakarathna R. Virtual care rapid scoping: main report. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2022 December (CADTH Health Technology Review).
Vegesna A, Tran M, Angelaccio M, Arcona S. Remote patient monitoring via non-invasive digital technologies: A systematic review. Telemedicine and e-Health. 2017;23(1):3-17.
Morrison P, Wang G, Estes M, Sharif B, Shaw E, Cowling T, Tay J, Jimenez-Zepeda VH, Far b, Amannejad Y. Toward Standardized Structured Reporting for the Management of Multiple Myeloma in Alberta: Insights in Application of Machine Learning. Presented at the 2020 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium (e-poster Gallery). View here.
Katzberg H, Siddiqi ZA, Mwaikambo B, Assimakopoulos E, Moulten K, Brown KE, Massie R, Bril V. Physician Insights on CIDP Care in Canada: Unmet Needs, Access Barriers, and Efgartigimod SC. Value in Health. 2026; 29(S6). Presented at ISPOR 2026.
Gerber B, Cowling T, Chen G, Yeung M, Duquette P, Schecter R, & Haddad P. MS patient characteristics and healthcare resource utilization from administrative databases: real-world evidence from Alberta, Canada. Presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Sept 2016; London, UK.
Gerber B, Cowling T, Chen G, Haddad P. Linking Administrative Data Sets from Alberta, Canada to Examine the Impact of Treatment Adherence on Health Care Resource Utilization Among Multiple Sclerosis Patients. Presented at the 2017 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, April 2017; Ottawa, Canada.
Gerber B, Cowling T, Chen G, Rivest D, Yeung M, Duquette P, Kindudu C, Barbeau M & Haddad P. The Impact of Treatment Adherence on Clinical and Economic Outcomes in Multiple Sclerosis: Real-World Evidence from Alberta, Canada [Abstract]. Value in Health. Nov 2016; 19(7): page A437.
Gerber B, Cowling T, Chen G, Yeung M, Duquette P, Haddad P. The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: Real world evidence from Alberta, Canada. Multiple Sclerosis and Related Disorders 2017; 18(Supplement C): 218-24.
Oliveira T, Kendler D.L, Schneider P, Juby A.G., Wani R.J., Packalen M, Avcil S, Li S, Waters-Banker C, Graves E, McMullen S & Brown J. Trends in osteoporotic fracture and related in-hospital complications during the COVID-19 pandemic in Alberta, Canada. Arch Osteoporosis. 2022; 17(109).
Oliveira T, Brown J, Juby A.G. Schneider P, Wani R.J. Packalen M, Avcil S, Li S, Farris M, Graves E, McMullen S & Kendler D.L. Trends in osteoporosis care patterns during the COVID-19 pandemic in Alberta, Canada. Arch Osteoporosis. 2022; 17(110).
Larkin-Kaiser K, Waters-Banker C, Cowling T, Snow L.A., Hasani I, Fernet M. Canadian Real-World Evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis: a systematic literature review. Value in Health, Volume 22, S707.
Pearson GJ, Manivong P, Pham T, Shaw E, et al. Lipoprotein(a) levels and major adverse cardiovascular events in Alberta, Canada: a retrospective cohort study. CJC Open. 2026. doi:10.1016/j.cjco.2026.03.015.
Manivong P, Shaw E, Pham T, et al. Characterization of lipoprotein (a) testing in Alberta, Canada: a retrospective cohort study. Atherosclerosis. 2025 Sep;408:120458.
Chen G, Farris MS, Cowling T, Colgan S, Xiang P, Pericleous L, Rogoza RM, Anderson TJ. Atherosclerotic Cardiovascular Diseases and Low-Density Lipoprotein Cholesterol Management in Alberta, Canada. Circulation. 2018;138:A142-72.
Chen G, Farris M, Cowling T, Tai M, Pinto L, Colgan S, Rogoza RM, Anderson TJ. Low-density Lipoprotein Cholesterol Management in Patients with Atherosclerotic Cardiovascular Diseases and Pre-existing Diabetes in Alberta, Canada. American Diabetes Association (ADA) 79th Scientific Sessions 2019; June 8, 2019; San Francisco, California.
Chen G, Farris M, Cowling T, Colgan SM, Xiang P, Pericleous L, Rogoza RM, Tai M, Anderson T. Treatment and Low-density Lipoprotein Cholesterol management in patients diagnosed with clinical Atherosclerotic Cardiovascular Disease in Alberta. Canadian Journal of Cardiology 2019;35(7):884-89.1
Chen G, Sharif B, Farris M, Cowling T, Pinto L, Rogoza R, Fairbarin M, Anderson T. Healthcare resource utilization and associated costs among patients with atherosclerotic cardiovascular diseases in Alberta, Canada. Canadian Journal of Cardiology 2020;30(10): S20.
Scory T, Chen G, Farris M, Shih YH, Pinto L, Cowling T. Lipid-lowering therapy patterns and low-density lipoprotein-cholesterol management among patients with acute myocardial infarction in Alberta, Canada. American College of Cardiology (ACC).20/World Congress of Cardiology (WCC) Virtual; March-June 2020;
Rogoza R, Oh P, Goeree R, Goodman S, Fairbairn M, Mackinnon E, Pericleous L, Motsepe-Ditshego P, Anderson T. Patterns of low-density lipoprotein cholesterol management and goal attainment in patients with atherosclerotic cardiovascular disease aged 65 years and older from Alberta and Ontario. Presented at: Canadian Cardiovascular Congress 2020; October 22-25, 2020; Virtual. (Medlior acknowledged for data analysis).
Chen G, Farris MS, Cowling T, Pinto L, Rogoza R, MacKinnon E, Champsi S, Anderson TJ. Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study. Clin Cardiol. 2021
Goodman SG, Mackinnon ES, Gregorie JC, Raggi P, Wani R, Packalen M, Avcil S, Farris MS, Graves E, Cowling T, Anderson TJ. COVID-19 Pandemic Induced Disruptions in Troponin and Low-Density Lipoprotein Cholesterol Laboratory Test Volumes Across Alberta. Canadian Congress of Cardiology, October 20-23, 2021 (Virtual).
Mackinnon ES, Anderson TJ, Raggi P, Gregorie JC, Wani R, Packalen M, Oliveira T, Li S, McMullen S, Cowling T, Goodman SG. Trends in Major Adverse Cardiac Events During the COVID-19 Pandemic in Alberta, Canada. American Heart Association Scientific Sessions 2021, November 13-15, 2021 (Virtual).
Mackinnon ES, Har B, Champsi S, Wani RJ, Geyer L, Shaw E, Farris MS, Anderson TJ. Guideline LDL-C threshold achievement in acute myocardial infarction patients: A real-world evidence study demonstrating the impact of treatment intensification with PCSK9i. Cardiology and Therapy. 2023; 12:327-38.
Mackinnon ES, Anderson T, Raggi P, Gregoire J, Wani RJ, Packalen MS, Graves E, Ekwaru P, McMullen S, Goodman SG. Trends in major adverse cardiac events and healthcare utilization during the COVID-19 pandemic in Alberta, Canada. CJC Open. 2023 Jun 22.
Mackinnon, E.S., Leiter, L.A., Wani, R.J. et al. Real-World Risk of Recurrent Cardiovascular Events in Atherosclerotic Cardiovascular Disease Patients with LDL-C Above Guideline-Recommended Threshold: A Retrospective Observational Study. Cardiol Ther. 2024; 13: 205–220.
Manivong P, Shaw E, Pham T, Leclerc P, Fortier J, Wilde T, Anderson T. Lipoprotein (a) levels and major adverse cardiovascular events in Alberta, Canada: a retrospective cohort study. Canadian Journal of Health Technologies. 2024; 4 (11).
Senior P, Hahn J, Mau G, Manivong P, Shaw E. Evidence of clinical inertia from a retrospective cohort analysis of basal insulin initiation in type 2 diabetes mellitus in a Canadian cohort using administrative health data in Alberta, Canada. Presented at: Vascular 2023; Montreal, Canada.
Senior P, Goldenberg R, Demchuk A, Klimek-Abercrombie A, Mau G, Moura CS, Filkowski J, Connelly K. Real-world use of guideline-directed cardioprotective therapy in type 2 diabetes mellitus with atherosclerotic cardiovascular disease: A retrospective cohort analysis using administrative health data in Alberta, Canada. Presented at: Vascular 2023; October 27, 2023; Montreal, Canada.
Senior, P, et al. Basal Insulin Initiation in Adults With Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using Administrative Health Data in Alberta, Canada. Canadian Journal of Diabetes. 2024; 48 (6):, 379 – 386.
Hawes C, Harris S, Mubarack F, Hinds D, Cowling T, Waters-Banker C, Farris M, About-Setta A. Comparative effectiveness and safety, and health-related quality of life of haemophilia A treatments: A systematic review. (2020), Abstracts. Haemophilia, 26: 27-181. The European Association for Haemophilia and Allied Disorders (EAHAD) View on Medlior.
Lau D, Shaw E, McMullen S, Cowling T, Witges K, Amitay E, Steubl D, Girard L. WCN23-0604 Acute and chronic complication profiles among patients identified with chronic kidney disease in Alberta, Canada. Kidney International Reports. 2023;8(3):S174.
Lau, D.C., Shaw, E., McMullen, S. et al. Acute and chronic complication profiles among patients with chronic kidney disease in Alberta, Canada: a retrospective observational study. BMC Nephrol 25, 244 (2024).
Lau. et al. Prevalence of Adult Type 2 Diabetes Mellitus and Related Complications in Alberta, Canada: A Retrospective, Observational Study Using Administrative Data. Canadian Journal of Diabetes. 2024; 48(3): 155.
Chen G, Sharif B, Gerber B, Farris M, Cowling T, Cabalteja C, Wu JW, Maturi B, Klein-Panneton K, Mah JK. A population-based study examining the epidemiologic burden, healthcare resource utilization and costs of spinal muscular atrophy in Alberta, Canada. Presented at the 25th International Annual Congress of the World Muscle Society, October 1, 2020; Virtual Congress. Neuromuscular Dystrophy Journal.
McMillan H, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, Maturi B, Klein-Panneton K, Cabalteja C, Lochmuller H. Disease and treatment burden of spinal muscular atrophy on patients and caregivers in Canada. Presented at the 25th International Annual Congress of the World Muscle Society, October 1, 2020; Virtual Congress. Neuromuscular Dystrophy Journal.
Chen G, Sharif B, Gerber B, Farris MS, Cowling T, Cabalteja C, Wu JW, Maturi B, Klein-Panneton K, Mah JK.(2021) Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada, Journal of Medical Economics, 24:sup1, 51-59.
McMillan HJ, Gerber B, Cowling T, Khuu W, Mayer M, Wu JW, Maturi B, Klein-Panneton K, Cabalteja C, Lochmüller H. Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada. J Neuromuscul Dis. 2021;8(4):553-568.
Budd N, Mestre T, Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu J, Maturi B, Cowling T. Evaluation of Health-Related Quality of Life for Individuals with Huntington’s Disease and Care Partners in Canada. International Congress of Parkinson’s Disease and Movement Disorders (MDS) Congress 2021, September 17-22 (Virtual).
Budd N, Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu JW, Maturi B, Cowling T, Mestre TA. Disease Burden of Huntington’s Disease in a Canadian Setting Using Administrative Health Data. The 28th Annual Meeting of the Huntington Study Group (HSG 2021), November 4-6 (Virtual).
Shaw E, Mayer M, Ekwaru P, McMullen S, Graves E, Wu JW, Budd N, Maturi B, Cowling T Mestre TA. Epidemiology and economic burden of Huntington’s Disease: a Canadian provincial public health system perspective, Journal of Medical Economics. 2022;25(1):212-9.
Graves, E, Cowling, T, McMullen, S, Ekwaru, P, Pham, T, Mayer, M, Ladouceur, MP, Hubert, M, Bougie, J, Amoozegar, F (2023). Migraine Treatment and Healthcare Resource Utilization in Alberta, Canada. Can J Neurol Sci, 1-11.
McMullen S, Graves E, Ekwaru P, Pham T, Mayer M, Ladouceur MP, Hubert M, Bougie J, Amooozegar F. Burden of episodic migraine, chronic migraine, and medication overuse headache in Alberta. Can J Neurol Sci, 1-11. 2023.
Ismail Z, Wilson M, Khalifa H, Belovich D, Shaw E, Pham T, McMullen S, Chen Y, Sadman N, Cai J, Zulkermine F, Barber D. Use of natural language processing to examine real-world clinical practice patterns in patients with dementia and Alzheimer’s disease in one primary care practice in Ontario, Canada. Presented at: 11th Canadian Conference on Dementia; November 2-4, 2023; Toronto, Canada.
Graves EB, Gerber BR, Berrigan PS, Shaw E, Cowling TM, Ladouceur MP, Bougie JK. Epidemiology and treatment utilization for Canadian patients with migraine: a literature review. Journal of International Medical Research. 2022;50(9).
Tay J, Chen G, Cowling T, Shaw E, Farris M, Liu F F, Victor H. Jimenez-Zepeda Early mortality following diagnosis of multiple myeloma from 2011 to 2016 in Alberta, Canada: Initial results from the population-based Identifying Outcomes in Real-World Multiple Myeloma (INFORMM) study. Accepted for the 2019 ASCO Annual Meeting. Journal of Clinical Oncology 37, 2019 (suppl; abstr e19509). More.
Shaw E, Liu F, Tay J, Jimenez-Zepeda VH, Chen G. Identifying Outcomes in Real-World Multiple Myeloma (INFORMM): Insights in Methodology for Using Administrative Health Data in Alberta. Presented at the 2019 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium; April 14–16, 2019; Edmonton, AB, Canada. More.
Jimenez-Zepeda VH, Chen G, Cowling T, Shaw E, Farris M, Liu FF, Tay J. Multiple Myeloma Treatment Landscape from 2011 to 2017 in Alberta, Canada: Results from the Population-Based “Identifying Outcomes in Real-World Multiple Myeloma” (INFORMM) Study. Presented at the 24th Congress of the European Hematology Association (EHA); June 13–16, 2019; Amsterdam, Netherlands.
Farris M, White K, Liu FF, Cowling T. A Rapid Literature Review of Real-World Evidence in Multiple Myeloma: Patient Characteristics and Health Outcomes. Presented at The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe 2018, November 2018; Barcelona, Spain.
Franek J, Cappelleri JC, Larkin-Kaiser KA, Wilner KD, Sandin R. Systematic review and network meta-analysis of first-line therapy for advanced EGFR-positive non-small-cell lung cancer. Future Oncology. 2019;15(24):2857-71. More.
Farris M, Larkin-Kaiser KA, Scory T, Boyne D, Wilner KD, Pastel M, Cappelleri JC, Ivanova JI. Network meta-analysis of first-line therapy for advanced EGFR mutation-positive non-small-cell lung cancer: updated overall survival. Future Oncology.2020; 16(36):3107-116.
Nakagawa K, Matsumura K, Larkin-Kaiser KA, Scory T, Farris M, Kikkawa H, Ivanova J, Wilner K. Indirect Analysis of First-line Tyrosine Kinase Inhibitors for EGFR+ NSCLC in Japanese patients. Presented at: 61st Annual Meeting of the Japan Lung Cancer Society; 2020; Okayama, Japan.
Larkin-Kaiser K, Scory T, Farris M, Wilner K, Ivanova J. PCN14 Updated Network Meta-analysis of First-line EGFR-targeted Tyrosine Kinase Inhibitor Treatments for Locally Advanced or Metastatic Non-small Cell Lung Cancer with EGFR-activating Mutations. Value in Health. 2020;23(Supplement 1): S24.
Nakagawa K, Matsumura K, Scory T, Farris M, Larkin-Kaiser KA, Kikkawa H, Ivanova JI, Wilner KD. Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population. Future Oncology. 2020.
Ramsahai JM, Randhawa A, Shephard C, Foster A, Geyer L, Manivong P, Graves E, McMullen S. A population-based study of the burden of severe asthma in Alberta, Canada. Can J Respir Crit Care Sleep Med. 2023;7(4):192-200.
Bhutani M, Randhawa A, Talukdar M, Manivong P, Fearon D, Gelfand A, Graves E, McMullen S, Mayers I. Associations between medication use, exacerbations, and healthcare utilization in COPD: a population-based study. Presented at: Canadian Respiratory Conference; April 20-22, 2023; Montreal, Canada.
Ramsahai JM, Randhawa A, Geyer L, Robert N, Manivong P, Shephard C, Foster A, Gelfand A, Graves E, McMullen S. A population-based study of severe asthma exacerbations and symptom control in Alberta, Canada. Presented at: Canadian Respiratory Conference; April 20-22, 2023; Montreal, Canada.
Hawkins N, Vogelmeier CF, Simons SO, Garbe E, Manito N, Swart KMA, Ekwaru P, Kossack N, Hernandez I, Mullerova H, Randhawa A, van Burk L, Sanchez-Covisa J, Rhodes K, Nordon C on behalf of the EXACOS-CV study group. Increased risk of decompensated heart failure, acute coronary syndrome, arrhythmias and ischaemic stroke following exacerbations of COPD: results from a multi-database cohort study. Presented at: ESC Congress 2023; August 25-28, 2023; Amsterdam, Netherlands.
Licskai C, Kayaniyil S, Hussey A, Manivong P, McMullen S, Ferrone M, Talukdar M. Regional variation of COPD burden in Alberta, Canada. Presented at: European Respiratory Society International Congress; September 9-13, 2023; Milan, Italy.
Vogelmeier C, Simons SO, Garbe E, Sin DD, Hawkins NM, Manito N, Santos S, Polinder K, Lobier M, Ekwaru P, Kossack N, Hernandez I, Mullerova H, Randhawa A, van Burk L, Sanchez-Covisa J, Rhodes K, Nordon C on behalf of the EXACOS-CV study group. Increased risk of severe cardiovascular events following exacerbations of COPD: a multi-database cohort study. Presented at: ERS Congress 2023; September 9-13, 2023; Milan, Italy.
Bhutani M, Talukdar M, Randhawa A, Manivong P, Gelfand A, McMullen S, Mayers I. Short-acting beta agonist (SABA), antibiotics, oral corticosteroid (OCS) and risk of mortality and cardiopulmonary events in patients with chronic obstructive pulmonary disease (COPD). Presented at: CHEST 2023; October 8-11, 2023; Honolulu, USA.
Ramsahai JM, Randhawa A, Foster A, Geyer L, McMullen S. The risk of exacerbation with elevated biomarkers, and real-world biomarker variability, in patients with severe asthma: A retrospective population-based study. Presented at: CHEST 2023; October 8-11, 2023; Honolulu, USA.
Parsekar K, Kossack N, Hernández I, Vogelmeier CF, Kolb N, Baak BN, Swart KMA, Simons SO, Bengtsson C, Vojinovic D, Sin DD, Hawkins NM, McMullen S, Pham T, García CC, Martínez N, Hernández JSC, Abram M, Halbach M, van Burk L, Randhawa A, Nordon C. Healthcare resource utilisation and costs in patients experiencing severe cardiac events following a COPD exacerbation: results from EXACOS-CV studies in Spain, Germany, the Netherlands and Canada. Presented at: ISPOR Europe 2023; November 12-15, 2023; Copenhagen, Denmark.
Hamilton MA, Sayani A, Kayaniyil S, McMullen S, Manivong P, McDonald T, Folkins C, Miah P, Hussey A, Ferrone M, Lachaine J, Beauchemin C, Licskai CJ. Leveraging real-world data (RWD) to improve COPD management and patient outcomes across Canada. Canadian Journal of Health Technologies. 2024; 4 (12).
Ekwaru JP, McMullen S, Cowling T, Bhutani M, van der Laan M. Benefits of Inhaled Corticosteroids (ICS) in COPD Maintenance Combinations: Real-World Evidence Using Longitudinal Targeted Maximum Likelihood Estimation. 2024-11, ISPOR Europe 2024, Barcelona, Spain. Value in Health. 2024; 27 (12), S2.
Ramsahai, J. M., Randhawa, A., Foster, A., Geyer, L., & McMullen, S. Real-world biomarker variability and effects of biologics on severe asthma in Alberta. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine. 2024; 8(5):198–207.
Hawkins NM, Nordon C, Rhodes K, Talukdar M, McMullen S, Ekwaru P, Pham T, Randhawa AK, Sin DD. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease. Heart. 2024;110(10):702-709.
Bhutani M, et al. Short-Acting Beta-Agonists, Antibiotics, Oral Corticosteroids, and the Associated Burden of COPD. CHEST Pulmonary 2024; 2 (3): 100042.
Hawkins NM, Randhawa AK, Nordon C, et al., ERJ Open Res 2025; 11: 01212-2024.
St Michael’s Hospital, Medlior, WSIB, Dr. S Tarlo, Dr. A Lau and Dr. A Adisesh. Chronic obstructive pulmonary disease – Discontinuation of smoking offset for non-economic loss benefits. Causes, diagnosis, and profession of COPD following workplace exposure to vapours, gases, dust and fumes ; February 2021;
Palmer JB, Li Y, Herrera V, Liao M, Tran M, Ozturk ZE. Treatment patterns and costs for anti-TNF-alpha biologic therapy in patients with psoriatic arthritis. BMC Musculoskeletal Disorders. 2016;17:261. (Medlior acknowledged for writing).
Expert Insights to Empower Health Outcomes Research.
Latest Blogs

Beyond clinical endpoints: HTA has a measurement problem
In 2026, real-world evidence will be judged not by volume, but by credibility. Regulators, HTA…

Medlior and CF Announce Strategic Partnership to Accelerate Multinational Real-World Evidence for Global Life Sciences Research
In 2026, real-world evidence will be judged not by volume, but by credibility. Regulators, HTA…

Reflecting on 2025, looking to 2026: Experts discuss what counts as high-value RWD, and how evidence generation is changing
In 2026, real-world evidence will be judged not by volume, but by credibility. Regulators, HTA…

Unlocking the Potential of Canadian Health Data: Transforming Insights into Action with RWE (via BecarisPublishing.com)
This Becaris Publishing report explores how real-world evidence is being used to turn Canada’s health…

Peering into the Crystal Ball: Experts Predict the Future of RWE, HTA, and Value-Based Healthcare (via BecarisPublishing.com)
A forward-looking Becaris Publishing report featuring expert predictions on the future of real-world evidence, HTA,…

Unlocking the Potential of Big Data: Transforming Healthcare in Canada and the UK Through Innovation (via BecarisPublishing.com)
A Becaris Publishing report comparing how Canada and the UK use big data to innovate…

From Theory to Practice: Implementing Targeted Learning and Causal Inference Using Real-World Data (via BecarisPublishing.com)
This Becaris Publishing report explores how causal inference and targeted learning methods are applied to…

ISPOR 2024 in Atlanta!
Medlior was delighted to attend the ISPOR 2024 Annual Meeting held in Atlanta. Key areas…

Harnessing Artificial Intelligence and Natural Language Processing for Data-Driven Healthcare Decisions
Medlior can help unlock the potential value of AI and NLP in your RWE projects.…

Realizing Fit-for-Purpose Real-World Data (via BecarisPublishing.com)
A Becaris Publishing report examining what makes real-world data suitable for evidence-based decision-making.

ISPOR EU 2023 in Copenhagen
This year’s theme was “HEOR at the Nexus of Policy and Science” and, as with…

Real-World Radar: The First Online Directory for Real-World Data (via BecarisPublishing.com)
This Becaris Publishing report introduces Real-World Radar, a centralized directory for accessing real-world healthcare data…
The Canadian Rare Disease Directory
Developed in partnership with Takeda Canada, our platform is dedicated to fostering connections, raising awareness, and sharing valuable information about organizations making impactful contributions to the rare disease community in Canada.
Discover concise profiles and direct links to organizations actively engaged in rare disease research, treatment, and innovation across Canada. Our aim is to establish this platform as a valuable resource, simplifying navigation through the intricate landscape of Rare Disease Research in Canada


Organizations
Alberta Children’s Hospital
Alberta Children’s Hospital is dedicated to advancing care for children with rare diseases through cutting-edge research and clinical programs. Their initiatives include collaborations with research institutes to develop innovative diagnostics and treatments for pediatric patients. The hospital also emphasizes family-centered care, ensuring that patients and their families are supported throughout their healthcare journey. Their work has had a transformative impact on the lives of children across Canada.
Alberta Children’s Hospital Research Institute (ACHRI)
ACHRI conducts groundbreaking research on rare pediatric diseases, integrating genetics, genomics, and precision medicine to develop novel solutions. The institute fosters collaboration among scientists, clinicians, and patients to improve health outcomes for children with rare conditions. ACHRI also contributes to education and training, equipping the next generation of researchers to tackle rare disease challenges. Their work bridges the gap between discovery and clinical care, ensuring their findings translate into meaningful patient benefits.
Canadian Institute for Health Information (CIHI)
CIHI advances rare disease research by providing robust health data and analytics to support evidence-based decision-making. They work with national and provincial partners to improve data collection, enabling better tracking of rare diseases and their impact on healthcare systems. CIHI’s contributions are essential for shaping policies and improving care for individuals with rare conditions across Canada.
Canadian Institutes of Health Research (CIHR)
CIHR plays a pivotal role in funding and supporting rare disease research across Canada. Through the Rare Disease Research Initiative, they foster collaboration among researchers, clinicians, and patients to address knowledge gaps and improve health outcomes. CIHR’s efforts include funding for national clinical trials, preclinical research, and the development of data-sharing platforms. These initiatives ensure Canada remains at the forefront of rare disease research.
Canadian Neuromuscular Disease Registry (CNDR)
CNDR collects and manages data on individuals with neuromuscular diseases, providing a critical resource for research and clinical care. The registry supports national and international studies, enabling the development of new treatments and improving patient outcomes. CNDR also facilitates collaborations between researchers, clinicians, and patients to advance understanding and care for rare neuromuscular conditions.
Canadian Rare Disease Network (CRDN)
The Canadian Rare Disease Network (CRDN) is a pan-Canadian network launched in 2024, uniting clinical, scientific, and patient expertise to advance care, research, and innovation for rare diseases. The network aims to bridge gaps in rare disease management through collaboration across Canada and internationally. CRDN promotes advocacy, knowledge sharing, and improved access to care for rare disease patients.
Care4Rare
Care4Rare is a pan-Canadian collaborative focused on improving the diagnosis, management, and treatment of rare diseases. By leveraging genomic technologies and patient-centered research, Care4Rare has successfully identified new rare diseases and developed innovative diagnostic tools. Their work also emphasizes knowledge sharing and education, ensuring that healthcare providers are equipped to meet the needs of rare disease patients.
Centre for Molecular Medicine and Therapeutics (CMMT)
The Centre for Molecular Medicine and Therapeutics (CMMT) at the University of British Columbia focuses on discovering genetic susceptibilities to illnesses, including rare neurological conditions. Their research integrates molecular biology, genomics, and clinical science to improve diagnostics and treatments. CMMT is a leader in advancing precision medicine and translating scientific discoveries into clinical applications.
Children’s Hospital of Eastern Ontario (CHEO)
CHEO Research Institute is a leader in rare disease research, focusing on conditions like mucopolysaccharidosis (MPS) and phenylketonuria (PKU). They have launched patient registries to improve care and outcomes for affected families. CHEO also works to integrate advanced diagnostic tools and therapeutic approaches, ensuring that children with rare diseases receive timely and effective treatment. Their efforts are a cornerstone of pediatric rare disease care in Canada.
Cystic Fibrosis Canada
Cystic Fibrosis Canada is a charitable organization established in 1960 to improve the lives of people with cystic fibrosis through research, advocacy, and care. The organization funds scientific studies, supports patients and their families, and raises awareness about cystic fibrosis as a rare genetic condition. Their comprehensive approach has significantly improved outcomes for individuals across Canada.
Genome Canada
Genome Canada supports large-scale research projects aimed at unlocking the genetic underpinnings of rare diseases. Through funding, collaboration, and innovation, they accelerate the discovery of new genes and therapies. Their initiatives also include public engagement and education, ensuring that genomic advancements are accessible and impactful for patients and their families. Genome Canada’s work has revolutionized the landscape of rare disease research in Canada.
Health Data Research Network (HDRN)
HDRN Canada connects researchers to multi-jurisdictional data, enabling large-scale studies on rare diseases. Their network facilitates collaborations across provinces, breaking down data silos to generate actionable insights. By integrating health system data with research, HDRN Canada is helping to transform how rare diseases are understood and managed.
INFORM RARE
INFORM RARE is a collaborative network co-designed by patients, families, and healthcare providers. The initiative focuses on generating high-quality evidence to support decision-making for therapies targeting rare genetic diseases in children. By prioritizing patient engagement, INFORM RARE ensures that research is aligned with real-world needs and that its findings directly benefit affected families.
London Health Sciences Centre
London Health Sciences Centre (LHSC) is actively involved in clinical research and trials for rare diseases, contributing to advancements in treatment and patient care. Their researchers focus on innovative approaches to diagnostics, therapy development, and improving health outcomes. LHSC’s multidisciplinary teams work closely with patients and families, ensuring comprehensive support and care for those affected by rare conditions. Their efforts have established them as a key player in Canada’s rare disease research community.
Maternal Infant and Youth Research Network (MICYRN)
MICYRN supports rare disease research related to mothers, infants, and youth, aiming to improve early diagnosis and treatment. Their initiatives include facilitating clinical trials, building research capacity, and supporting data-sharing networks. MICYRN’s holistic approach ensures that their research addresses both medical and social dimensions of rare disease care.
McGill University
McGill University is home to world-renowned research initiatives focusing on rare diseases, particularly through The Montreal Neurological Institute and Hospital (The Neuro). The Rare Neurological Diseases Group at The Neuro prioritizes advancing research and clinical care for conditions like amyotrophic lateral sclerosis (ALS) and Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS). They focus on developing new diagnostic methods, innovative treatments, and improving the overall understanding of rare neurological conditions. McGill’s multidisciplinary collaborations ensure that their findings have both local and global impacts.
Montreal Neurological Institute (The Neuro)
The Neuro at McGill University is a hub for rare neurological disease research, integrating cutting-edge science with patient-focused care. Their Rare Neurological Diseases Group tackles some of the most complex conditions, utilizing advanced imaging, genetics, and neuroinformatics. The Neuro’s Open Science philosophy ensures that their findings are shared globally, accelerating progress in understanding and treating rare diseases. Their work has a transformative impact on both research and clinical practices worldwide.
Myeloma Canada
Myeloma Canada is a national non-profit organization dedicated to improving the lives of Canadians affected by multiple myeloma, a rare form of cancer. Founded in 2005, the organization supports research, provides education, and advocates for access to effective treatments. Their efforts include funding clinical trials and fostering collaboration within the healthcare community.
Newborn Screening Ontario (NSO)
NSO is Canada’s largest newborn screening program, detecting rare diseases in infants to enable early intervention and treatment. Their comprehensive approach combines advanced diagnostic technologies with research initiatives to improve outcomes for newborns. NSO also engages in public education and advocacy to raise awareness about the importance of early screening.
Ottawa Hospital Research Institute (OHRI)
OHRI conducts pioneering research on rare diseases, with a focus on translational medicine and clinical applications. Their scientists work on identifying novel biomarkers, developing therapies, and improving diagnostics. OHRI collaborates with national networks to ensure their research addresses the most pressing needs in rare disease care. By bridging the gap between laboratory discoveries and patient treatment, they play a crucial role in advancing healthcare for rare disease patients.
Rare Alliance Canada (RAC)
Rare Alliance Canada (RAC) is a coalition of patient support groups, non-profits, researchers, healthcare organizations, and industry partners dedicated to improving outcomes for Canadians with rare diseases. RAC fosters collaboration among stakeholders to advance rare disease policy and solutions. They also engage with international alliances to share expertise and best practices.
Regroupement Québécois des Maladies Orphelines (RQMO)
RQMO advocates for individuals with rare diseases in Quebec, providing education, support, and resources. The organization collaborates with researchers and policymakers to address gaps in care and improve access to treatments. RQMO also focuses on raising awareness about the challenges faced by rare disease patients, ensuring their voices are heard.
The Canadian Forum for Rare Disease Innovators (RAREi)
RAREi is an informal network of Canadian biopharmaceutical organizations focused on developing therapeutics for rare diseases. The group serves as a forum to address public policy issues, foster collaboration, and drive innovation in rare disease research and treatment. Their efforts support improved patient access to emerging therapies and global partnerships.
The Hospital for Sick Children (SickKids)
SickKids is a global leader in pediatric rare disease research, focusing on genetic studies, innovative therapies, and patient care. Their researchers work on uncovering the causes of rare disorders and developing targeted treatments to improve the quality of life for children and their families. SickKids also participates in national and international clinical trials, providing access to cutting-edge therapies. Their commitment to knowledge sharing and collaboration has positioned the institution as a beacon of hope for families affected by rare diseases.
Université de Montréal
Université de Montréal is a key player in rare disease research in Canada, particularly in mitochondrial and genetic disorders. Researchers collaborate with institutions like The Neuro to deepen the understanding of these complex conditions and explore innovative therapies. Their work is bolstered by cutting-edge facilities and a strong commitment to translating scientific discoveries into clinical applications. Through these efforts, the university supports a wide range of patients and contributes to global advancements in rare disease care.
University Health Network (UHN)
UHN is one of Canada’s leading research institutions, contributing to rare disease research through innovative clinical trials and precision medicine initiatives. Their focus spans genetic research, advanced therapies, and improving patient access to care. UHN’s collaboration with international networks ensures their research aligns with global advancements, while their patient-centered approach addresses the unique challenges faced by those with rare conditions.
University of Alberta
The University of Alberta is a leader in addressing rare diseases through research and collaborative initiatives. Their contributions include exploring novel genetic insights, advancing precision medicine, and participating in national networks dedicated to improving diagnostics and treatments. The university is also instrumental in developing data-driven approaches to enhance healthcare delivery for rare disease patients. These efforts exemplify their commitment to improving health outcomes for some of the most vulnerable populations.
University of British Columbia (UBC)
UBC is at the forefront of rare disease research, with a focus on genetics and clinical trials. Their researchers collaborate nationally and internationally to uncover the underlying mechanisms of rare conditions and to develop new therapies. UBC is particularly engaged in initiatives that integrate genomic technologies into healthcare, aiming to transform patient care and improve outcomes. Their work has positioned UBC as a key hub for rare disease innovation.
University of Calgary
The University of Calgary has taken a leadership role in rare disease research through initiatives like the Rare Disease Administrative Data Research (RADAR) Team. This group evaluates the health system impacts of rare diseases, contributing to policy development and healthcare improvements. Their work integrates data analysis, clinical research, and patient advocacy to address unmet needs in rare disease care. By fostering interdisciplinary collaborations, the university continues to drive meaningful change.
University of Manitoba
The University of Manitoba contributes to rare disease research through innovative studies and participation in national networks. Researchers focus on understanding the genetic and molecular mechanisms of rare conditions, paving the way for new treatments. Their work also includes addressing healthcare disparities and improving access to care for patients in underserved communities. This commitment highlights the university’s role as a vital part of Canada’s rare disease research landscape.
University of Toronto
The University of Toronto is a powerhouse in rare disease research, leveraging its world-class facilities and collaborations. Researchers focus on uncovering genetic causes, developing novel therapies, and advancing clinical trials. The university plays a pivotal role in national and international research networks, ensuring its findings contribute to global progress. This work underscores its commitment to addressing the complex challenges of rare diseases.
York University
York University is involved in rare disease research with an emphasis on genetic studies and clinical applications. Their researchers collaborate with national initiatives to develop cutting-edge diagnostics and treatments. The university’s interdisciplinary approach combines basic science, healthcare innovation, and patient advocacy to improve the lives of those living with rare diseases. York’s dedication to social justice ensures that their research is both impactful and inclusive.

